drugset
Drugs / SARS-CoV-2 recombinant spike protein
last change Sep 2022 re-read 3 minutes ago

SARS-CoV-2 recombinant spike protein

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
Cinnagen · Vaxine Pty Ltd · Shahid Beheshti University of Medical Sciences

Trials 5

today NCT05231590 · Ph 3 NCT05285384 · not/applicable NCT05175625 · Ph 3 NCT05005559 · Ph 3 NCT04944368 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT04944368 May → Jul 2021 COVID-19 Cinnagen Completed No outcome recorded
Phase 33 trials · 2 met primary
Phase 3 NCT05231590 Feb → Apr 2022 COVID-19 Cinnagen Completed No outcome recorded
Phase 3 NCT05175625 Dec 2021 COVID-19 Cinnagen Completed Met primary
Phase 3 NCT05005559 Aug 2021 → Mar 2022 COVID-19 Cinnagen Completed Met primary
Phase not applicable1 trial
— NCT05285384 Feb → Mar 2022 COVID-19 Cinnagen Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as SARS-CoV-2 recombinant spike protein ClinicalTrials.gov intervention name — accepted as the source's own label NCT05285384 ↗
4

NCT05175625 ↗

NCT04944368 ↗

NCT05231590 ↗

NCT05005559 ↗
Modality Protein / enzyme biologic “candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine” NCT04944368 ↗
Route Intramuscular “administered with intramuscular injections in the non-dominant arm” NCT04944368 ↗